A Sinovac Biotech Ltd. minority stakeholder is voluntarily dismissing a suit against the vaccine maker and its controlling shareholder over the stock’s value and the balance of power on the board, according to a federal court filing.
Boston-based Heng Ren Investments LP didn’t give its reason for dropping the suit in the parties’ filing Thursday with the US District Court for the District of Massachusetts.
Neither Heng Ren’s founder and chief investment officer Peter Halesworth nor Sinovac immediately responded to requests for information about the dismissal, including whether a settlement is involved.
- Heng Ren alleged that Weidong Yin—Sinovac’s controlling shareholder, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.